Anupam Rasayan initiates Open Offer for Bliss GVS Pharma shares
Anupam Rasayan India Limited is making an open offer to acquire 26% of Bliss GVS Pharma Limited for up to ₹829.03 crore at ₹299 per share. This follows a SPA to acquire 43.30% of Bliss GVS Pharma's shares. The announcement details the offer and financial information for both companies.
The open offer for a significant stake (26%) in another company represents a major strategic move for Anupam Rasayan India Limited, impacting its market position and financial structure.
The announcement is a regulatory filing regarding an open offer, which is a standard corporate action. While it involves a significant transaction, there are no immediate positive or negative indicators within the provided text itself.
Anupam Rasayan India Limited has submitted a newspaper advertisement regarding a Detailed Public Statement for an Open Offer to acquire fully paid-up equity shares of Bliss GVS Pharma Limited. The offer is for up to 2,77,26,848 equity shares, representing 26.00% of Bliss GVS Pharma's expanded voting share capital, from public shareholders.
The open offer is being made pursuant to a Share Purchase Agreement (SPA) executed on May 23, 2026, where Anupam Rasayan agreed to acquire 4,58,03,024 equity shares, constituting 43.30% of Bliss GVS Pharma's equity share capital, at a price not exceeding ₹299.00 per equity share. The total consideration for the open offer, assuming full acceptance, is up to ₹829.03 crore.
The advertisement was published in "Financial Express" (English), "Jansatta" (Hindi), and "Nav Shakti" (Marathi) on June 1, 2026. Anupam Rasayan India Limited, engaged in specialty chemicals, reported total revenue of ₹2,383.63 crore and net income of ₹222.20 crore for the financial year ended March 31, 2026. Bliss GVS Pharma Limited, a pharmaceutical products manufacturer, reported total revenue of ₹1,000.64 crore and net income of ₹134.73 crore for the same period.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.